Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
AssigneeIconic Therapeutics LLC
InventorsJan-Willem Theunissen, Andrew D. Avery, II, Allen G. Cai, Anthony Byron Cooper, Thi-Sau Migone
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods of making and using the antibodies or ADCs, such as therapeutic and diagnostic methods.
Claims40
An isolated antibody which binds to human Tissue Factor (TF), wherein the isolated antibody comprises three heavy chain complementarity determining regions (CDRs) (VH-CDR1, VH-CDR2, and VH-CDR3) and three light chain complementarity determining regions (CDRs) (VL-CDR1, VL-CDR2, and VL-CDR3), wherein the VH-CDR1, VH-CDR2, and VH-CDR3 are from a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO:836, and wherein the VL-CDR1, VL-CDR2, and VL-CDR3 are from a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO:837.
An isolated antibody which binds to human TF and comprises three heavy chain complementarity determining regions (CDRs) (VH-CDR1, VH-CDR2, and VH-CDR3) and three light chain CDRs (VL-CDR1, VL-CDR2, and VL-CDR3), wherein:
- the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:
- 890, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:
- 891, and the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:
- 892, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:
- 893, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:
- 894, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:895, and wherein the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are defined according to the Kabat numbering system.
Dependencies are inferred from the claim text.